Pharma: Page 13
-
Daniel Tadevosyan via Getty Images
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.
By BioPharma Dive staff • Sept. 27, 2024 -
George Clerk via Getty Images
Pfizer to pull sickle cell drug from market, shut down trials
The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S. in 2019.
By Kristin Jensen • Sept. 26, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Mario Tama via Getty Images
Amgen claims success for two immune drugs, but results underwhelm Wall Street
Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.
By Kristin Jensen • Sept. 25, 2024 -
Chip Somodevilla via Getty Images
Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs
CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.
By Jonathan Gardner • Sept. 24, 2024 -
imyskin via Getty Images
Sponsored by AltasciencesThe golden era of GLP-1 drugs: Where we are and what comes next
GLP-1 drugs went from helping with blood sugar management to supporting weight loss. What’s next?
Sept. 23, 2024 -
Daniel Tadevosyan via Getty Images
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
By BioPharma Dive staff • Sept. 20, 2024 -
Daniel Tadevosyan via Getty Images
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
By BioPharma Dive staff • Sept. 18, 2024 -
Permission granted by AstraZeneca
Sanofi readies to meet US demand for RSV antibody
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in full supply this RSV season.
By Delilah Alvarado • Sept. 16, 2024 -
gorodenkoff via Getty Images
Sponsored by SASGenerative AI can enhance pharmaceutical innovation – but are you ready for it?
There’s no doubt that AI and GenAI can speed up pharmaceutical innovation. But before organizations can jump into the future, it’s crucial to understand the benefits – and the risks – of advanced technology.
By Susan Lenderts, Global Head of Life Sciences, SAS • Sept. 16, 2024 -
Maddie Meyer via Getty Images
Moderna, trailing rivals, checks its RSV shot expectations
During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.
By Delilah Alvarado • Sept. 13, 2024 -
Daniel Tadevosyan via Getty Images
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.
By BioPharma Dive staff • Sept. 13, 2024 -
JHVE Photo via Getty Images
Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic spontaneous urticaria.
By Kristin Jensen • Sept. 11, 2024 -
Daniel Tadevosyan via Getty Images
GSK discontinues herpes vaccine; Roivant launches new ‘vant’ around hypertension drug
The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity drug data and Lilly appointed a company veteran as its new CFO.
By BioPharma Dive staff • Sept. 11, 2024 -
Stock.adobe.com
Sponsored by Quest DiagnosticsAccelerating Alzheimer’s therapy innovation: A new horizon in blood-based biomarkers
The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis and treatment.
By Dr. Michael K. Racke, Medical Director, Neurology, Quest Diagnostics • Sept. 9, 2024 -
Daniel Tadevosyan via Getty Images
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion.
By BioPharma Dive staff • Sept. 6, 2024 -
selvanegra via Getty Images
Lilly builds case for weekly insulin shot
New data show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.
By Jonathan Gardner • Sept. 5, 2024 -
Daniel Tadevosyan via Getty Images
High-dose Spinraza meets study goal; Top Dyne executives exit
A new dose regimen of Biogen's spinal muscular atrophy drug appeared promising, while Denali Therapeutics and Regenxbio charted plans for drug approval applications.
By BioPharma Dive staff • Sept. 4, 2024 -
Permission granted by Novartis
Novartis builds out radiopharma production with expansion, new factory
A planned facility in California will boost Novartis’ West Coast supply chain as new uses for the company’s radioligand therapies grow.
By Kristin Jensen • Sept. 4, 2024 -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 4, 2024 -
Jezperklauzen via Getty Images
Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares
The company's value jumped by several billion dollars as trial results showed its experimental shot could match and, in some cases, even outperform Pfizer's market-leading Prevnar 20.
By Delilah Alvarado • Sept. 3, 2024 -
peterschreiber.media via Getty Images
Sanofi finds a silver lining in mixed MS drug results
Tolebrutinib, which Sanofi acquired in a $3.7 billion deal, failed two studies in people with relapsing disease, but succeeded in a type of multiple sclerosis that has no approved therapies.
By Ben Fidler • Sept. 3, 2024 -
Getty Images Signature via Canva.com
Sponsored by StoryfulScript for success: The value of digital insights in pharma
Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.
Sept. 3, 2024 -
Daniel Tadevosyan via Getty Images
Novo builds heart failure case for semaglutide; Ventyx CFO departs
A new analysis showed semaglutide reduced the risk of worsening heart failure. Elsewhere, the FDA OK’d a vaccine for mpox and a biotech planned layoffs.
By BioPharma Dive staff • Aug. 30, 2024 -
Kena Betancur via Getty Images
Keytruda fails lung and skin cancer trials, limiting further expansion
The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.
By Jonathan Gardner • Aug. 29, 2024 -
Mario Tama via Getty Images
J&J submits touted autoimmune disease drug for FDA approval
Nipocalimab is one of several drugs J&J has forecast for multi-billion dollar sales. The company’s initial application is for its use in myasthenia gravis.
By Kristin Jensen • Aug. 29, 2024
Previous
